Triaryl-ethylene derivatives
AssigneeMerrell Pharmaceuticals Inc.
InventorsDonald A. Kaplan, Donald P. Matthews, Alan J. Bitonti, William A. Van Sickle
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel triaryl-ethylene derivatives that are useful as anti-neoplastic agents, antiatherosclerotic agents, and hypocholesterolemic agents.
Claims12
A method of treating a patient afflicted with a neoplastic disease state selected from the group consisting of acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloblastic leukemia, chronic leukemia myelocytic;
- carcinomas and adenocarcinomas of the cervix, breast, prostate, esophagus, stomach, small intestines, colon and lungs;
- solid tumors of the breast, uterus, and cervix;
- oesteroma sarcoma, osteosarcoma, lipoma sarcoma, liposarcoma, hemangioma sarcoma and hemangiosarcoma;
- amelanotic melanomas and melanotic melanomas;
- and Hodgkins Disease comprising administering thereto of a therapeutically effective antineoplastic amount of a compound of formula ##STR37## wherein A is a radical of the formula ##STR38## wherein R and R.sub.1 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- and
- G is HN, H.sub.3 CN, CH.sub.2, or O;
- n is an integer from 4 to 12;
- R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, or hydroxy;
- R.sub.3 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, hydroxy, or --Y(CH.sub.2).sub.p A.sub.1 in which A.sub.1 is a radical of the formula ##STR39## wherein R.sub.4 and R.sub.5 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- G.sub.1 is HN, H.sub.3 CN, CH.sub.2, or O;
- and
- p is an integer from 4 to 12;
- X is chloro or bromo;
- Y is O or NH;
- or a pharmaceutically acceptable salt thereof.
A method of treating a patient at risk of developing a neoplastic disease state selected from the group consisting of acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloblastic leukemia, chronic leukemia myelocytic;
- carcinomas and adenocarcinomas of the cervix, breast, prostate, esophagus, stomach, small intestines, colon and lungs;
- solid tumors of the breast, uterus, and cervix;
- oesteroma sarcoma, osteosarcoma, lipoma sarcoma, liposarcoma, hemangioma sarcoma and hemangiosarcoma;
- amelanotic melanomas and melanotic melanomas;
- and Hodgkins Disease comprising administering thereto of a prophylactically effective antineoplastic amount of a compound of formula ##STR40## wherein A is a radical of the formula ##STR41## wherein R and R.sub.1 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- and
- G is HN, H.sub.3 CN, CH.sub.2, or O;
- n is an integer from 4 to 12;
- R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, or hydroxy;
- R.sub.3 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, hydroxy, or --Y(CH.sub.2).sub.p A.sub.1 in which A.sub.1 is a radical of the formula ##STR42## wherein R.sub.4 and R.sub.5 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- G.sub.1 is HN, H.sub.3 CN, CH.sub.2, or O;
- and
- p is an integer from 4 to 12;
- X is chloro or bromo;
- Y is O or NH;
- or a pharmaceutically acceptable salt thereof.
A method of treating a patient afflicted with a neoplastic disease state selected from the group consisting of acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloblastic leukemia, chronic leukemia myelocytic;
- carcinomas and adenocarcinomas of the cervix, breast, prostate, esophagus, stomach, small intestines, colon and lungs;
- solid tumors of the breast, uterus, and cervix;
- oesteroma sarcoma, osteosarcoma, lipoma sarcoma, liposarcoma, hemangioma sarcoma and hemangiosarcoma;
- amelanotic melanomas and melanotic melanomas;
- and Hodgkins Disease comprising administering thereto of a therapeutically effective antineoplastic amount of a compound of formula ##STR43## wherein A is a radical of the formula ##STR44## wherein R and R.sub.1 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- and
- G is HN, H.sub.3 CN, CH.sub.2, or O;
- n is an integer from 4 to 12;
- R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, or hydroxy;
- R.sub.3 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, hydroxy, or --Y(CH.sub.2).sub.p A.sub.1 in which A.sub.1 is a radical of the formula ##STR45## wherein R.sub.4 and R.sub.5 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- G.sub.1 is HN, H.sub.3 CN, CH.sub.2, or O;
- and
- p is an integer from 4 to 12;
- X is chloro or bromo;
- Y is O or NH;
- or a pharmaceutically acceptable salt thereof.
A method of treating a patient at risk of developing a neoplastic disease state selected from the group consisting of acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloblastic leukemia, chronic leukemia myelocytic, carcinomas and adenocarcinomas of the cervix, breast, prostate, esophagus, stomach, small intestines, colon and lungs;
- solid tumors of the breast, uterus, and cervix, oesteroma sarcoma, osteosarcoma, lipoma sarcoma, liposarcoma, hemangioma sarcoma and hemangiosarcoma;
- amelanotic melanomas and melanotic melanomas;
- and Hodgkins Disease comprising administering thereto of a prophylactically effective antineoplastic amount of a compound of formula ##STR46## wherein A is a radical of the formula ##STR47## wherein R and R.sub.1 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- and
- G is HN, H.sub.3 CN, CH.sub.2, or O;
- n is an integer from 4 to 12;
- R.sub.2 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, or hydroxy;
- R.sub.3 is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halogen, hydroxy, or --Y(CH.sub.2).sub.p A.sub.1 in which A.sub.1 is a radical of the formula ##STR48## wherein R.sub.4 and R.sub.5 are each independently hydrogen or C.sub.1 -C.sub.4 alkyl;
- G.sub.1 is HN, H.sub.3 CN, CH.sub.2, or O;
- and
- p is an integer from 4 to 12;
- X is chloro or bromo;
- Y is O or NH;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.